phenytoin has been researched along with ranitidine in 32 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (9.38) | 18.7374 |
1990's | 4 (12.50) | 18.2507 |
2000's | 12 (37.50) | 29.6817 |
2010's | 12 (37.50) | 24.3611 |
2020's | 1 (3.13) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Faller, B; Wohnsland, F | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Gozalbes, R; Pineda-Lucena, A | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Akamatsu, M | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Al-Ach, NN; Al-Tel, TH; Alshihabi, AM; Anbar, HS; El-Awady, R; El-Gamal, MI; El-Gamal, R; Kalla, RR; Munther, MA; Sbenati, RM; Shahin, AI; Shehata, MK; Tarazi, H; Tokatly, RT; Wahba, MM; Zaraei, SO | 1 |
Bramhall, D; Levine, M | 1 |
Hansky, J; Phillips, P | 1 |
Bochner, F; Hallpike, JF; Hann, CS; Hetzel, DJ; Shearman, DJ; Watts, RW | 1 |
Bachmann, KA; Jauregui, L; Levine, L; Miller, K; Reese, J; Sullivan, TJ | 1 |
Iagmin, P; Tse, CS | 1 |
Akinwande, KI; Biallowons, K; Tse, CS | 1 |
Boselli, L; Levati, A; Savoia, G; Tommasino, C; Zoppi, F | 1 |
Gorman, JM; Kalimuddin, MN; Khan, AY | 1 |
Budha, NR; Christensen, ML; Mehrotra, N; Meibohm, B; Zhang, Y | 1 |
Chen, SC; Dolton, MJ; McLachlan, AJ; Ng, K; Pont, L; Ray, JE | 1 |
2 review(s) available for phenytoin and ranitidine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Neuropsychiatric manifestations of phenytoin toxicity in an elderly patient.
Topics: Aged; Aged, 80 and over; Delirium; Drug Interactions; Female; Humans; Phenytoin; Polypharmacy; Ranitidine | 2007 |
1 trial(s) available for phenytoin and ranitidine
Article | Year |
---|---|
Peri-operative prophylaxis with phenytoin: dosage and therapeutic plasma levels.
Topics: Adult; Aged; Anticonvulsants; Cefazolin; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Female; Humans; Intraoperative Care; Male; Mannitol; Middle Aged; Phenobarbital; Phenytoin; Postoperative Complications; Premedication; Ranitidine; Seizures; Supratentorial Neoplasms | 1996 |
29 other study(ies) available for phenytoin and ranitidine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Design and synthesis of new quinoline derivatives as selective C-RAF kinase inhibitors with potent anticancer activity.
Topics: Antineoplastic Agents; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydroxyquinolines; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinolines; Sorafenib; Structure-Activity Relationship | 2022 |
Possible interaction of ranitidine with phenytoin.
Topics: Aged; Dementia, Multi-Infarct; Drug Interactions; Humans; Male; Phenytoin; Ranitidine; Seizures | 1988 |
Phenytoin toxicity secondary to cimetidine administration.
Topics: Aged; Cimetidine; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Peptic Ulcer; Phenytoin; Ranitidine | 1984 |
Lack of interaction between ranitidine and phenytoin.
Topics: Drug Interactions; Epilepsy; Furans; Humans; Phenytoin; Ranitidine | 1983 |
Drug interactions of H2-receptor antagonists.
Topics: Adolescent; Adult; Aged; Antacids; Biological Availability; Cimetidine; Drug Interactions; Famotidine; Histamine H2 Antagonists; Humans; Middle Aged; Nizatidine; Omeprazole; Phenytoin; Ranitidine; Theophylline | 1994 |
Phenytoin and ranitidine interaction.
Topics: Aged; Drug Interactions; Humans; Phenytoin; Ranitidine | 1994 |
Phenytoin concentration elevation subsequent to ranitidine administration.
Topics: Adult; Drug Interactions; Female; Humans; Phenytoin; Ranitidine | 1993 |
A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens.
Topics: Acetaminophen; Analgesics; Anticonvulsants; Bronchodilator Agents; Caffeine; Calibration; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Histamine H2 Antagonists; Humans; Infant, Newborn; Phenytoin; Quality Control; Ranitidine; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Theophylline | 2008 |
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Australia; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; Fungi; Humans; Logistic Models; Male; Metoclopramide; Middle Aged; Mycoses; Phenytoin; Ranitidine; Retrospective Studies; Rifampin; Triazoles | 2012 |